| Literature DB >> 12777705 |
Dean Dluzen1, Martin Horstink.
Abstract
In this review, we relate both laboratory and clinical evidence associated with the capacity for estrogen to function as a modulator of nigrostriatal dopaminergic pathology. To accomplish this goal, we have divided this review into three parts. In Part 1, we provide a brief historical perspective of studies that have laid the groundwork for demonstrating the existence of hormonal- nigrostriatal interactions. In Part 2, we focus specifically on laboratory data that show the ability and conditions by which estrogen may function as a neuroprotectant of the nigrostriatal dopaminergic system. Finally, in Part 3, we review the clinical literature related to this issue as a means for consideration of estrogen as a modulator, neuroprotectant, and therapy for Parkinson disease.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12777705 DOI: 10.1385/endo:21:1:67
Source DB: PubMed Journal: Endocrine ISSN: 1355-008X Impact factor: 3.633